There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Organogenesis Holdings (ORGO – Research Report) and Immuneering (IMRX – Research Report) with bullish sentiments.
Organogenesis Holdings (ORGO)
In a report released yesterday, Ryan Zimmerman from BTIG maintained a Buy rating on Organogenesis Holdings, with a price target of $4.00. The company’s shares closed last Thursday at $1.97, close to its 52-week low of $1.80.
According to TipRanks.com, Zimmerman is a 4-star analyst with an average return of
Organogenesis Holdings has an analyst consensus of Moderate Buy, with a price target consensus of $3.50.
See today’s best-performing stocks on TipRanks >>
Immuneering (IMRX)
In a report released yesterday, Geulah Livshits from Chardan Capital reiterated a Buy rating on Immuneering, with a price target of $21.00. The company’s shares closed last Thursday at $5.20, close to its 52-week low of $3.70.
According to TipRanks.com, Livshits is a 5-star analyst with an average return of
Currently, the analyst consensus on Immuneering is a Strong Buy with an average price target of $20.50, representing a 254.7% upside. In a report released yesterday, TD Cowen also maintained a Buy rating on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ORGO:
- Organogenesis Holdings Inc. Reports Third Quarter 2023 Financial Results
- Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2023 Financial Results on November 9, 2023
- Organogenesis Applauds Withdrawal of Local Coverage Determinations by Novitas, First Coast Service Options and CGS
- BTIG sees a win for Organogenesis from MAC decision on LCDs
